PORTLAND, OR--(Marketwired - Oct 17, 2013) - MolecularMD Corp., a molecular diagnostics company focused on providing the highest quality companion diagnostics and clinical trials support services to oncology drug developers, announced today that it will be presenting three posters at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 19-23 in Boston, MA. One presentation highlights MolecularMD's custom Next Generation Sequencing panel for blood-based evaluation of solid tumor mutation status by sequencing regions of interest in circulating tumor DNA. The other two presentations demonstrate MolecularMD's development and validation of robust immunohistochemistry assays for clinical trial applications.

Presentation Details
Title: Mutation detection in FFPE and plasma circulating DNA with a focused ALK-EGFR-KRAS Next-Generation Sequencing panel
Poster Session A: Pharmacogenetics, Pharmacogenomics, and Therapeutic Response
Date & Time: Sunday, October 20, 2013, 12:30 p.m. - 7:30 p.m.
Abstract No.: A208

Title: Evaluation of HGF and MET protein expression in NSCLC tumor specimens from patients previously treated with targeted or chemotherapies
Poster Session A: Biomarkers
Date & Time: Sunday, October 20, 2013, 12:30 p.m. - 7:30 p.m.
Abstract No.: A42

Title: Clinical assessment of MUC1 protein expression in FFPE tissue: Development and validation of an immunohistochemistry assay as a predictive assay for response to MUC1 vaccines
Poster Session B: Tumor Immunology Targets
Date & Time: Monday, October 21, 2013, 12:30 p.m. - 7:30 p.m.
Abstract No.: B297

About MolecularMD
MolecularMD Corporation develops and commercializes specialty molecular diagnostics for oncology applications. Its tests are designed to allow appropriate selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. MolecularMD incorporates gold-standard and innovative technologies in providing its partners with the highest quality results. Tests are designed to meet clinical trial needs, and MolecularMD has appropriate systems and standards in place to enable development of companion diagnostic tests in conjunction with partners' novel anticancer agents. A private company based in Portland, Oregon, MolecularMD was founded by Dr. Brian Druker, director of the Knight Cancer Institute at Oregon Health & Science University, and Sheridan G. Snyder, entrepreneur and founder of Genzyme Corporation.

Contact Information:

MolecularMD Contact:
Kate Corcoran, Ph.D.